Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to “Sell” at StockNews.com

StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) to a sell rating in a research report released on Saturday morning. A number of other research analysts also recently issued reports on MDGL. Citigroup reduced their price objective on Madrigal Pharmaceuticals from $382.00 to $371.00 and set a buy rating for the company in […]

Leave a Reply

Your email address will not be published.

Previous post Gibson Capital LLC Increases Holdings in Vanguard Small-Cap Value ETF (NYSEARCA:VBR)
Next post Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Carnegie Investment Counsel